Ieq Capital LLC Raises Position in Edwards Lifesciences Corporation $EW

Key Points

• Ieq Capital LLC increased its holdings in Edwards Lifesciences Corporation by 50.2%, acquiring 23,151 additional shares, bringing their total to 69,312 shares valued at approximately $5,024,000.
• Edwards Lifesciences reported a quarterly EPS of $0.67, exceeding analysts' expectations of $0.62, and had revenues of $1.53 billion for the quarter, a year-over-year increase of 11.9%.
• Analysts generally have a "Moderate Buy" consensus rating for Edwards Lifesciences, with an average target price of $85.90 across multiple firms.

Ieq Capital LLC increased its holdings in Edwards Lifesciences Corporation (NYSE:EW - Free Report) by 50.2% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 69,312 shares of the medical research company's stock after buying an additional 23,151 shares during the period. Ieq Capital LLC's holdings in Edwards Lifesciences were worth $5,024,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently bought and sold shares of EW. Brighton Jones LLC bought a new position in Edwards Lifesciences in the 4th quarter worth approximately $266,000. Bank Pictet & Cie Europe AG boosted its holdings in Edwards Lifesciences by 16.7% in the 4th quarter. Bank Pictet & Cie Europe AG now owns 10,231 shares of the medical research company's stock worth $757,000 after buying an additional 1,463 shares during the period. Integrated Wealth Concepts LLC boosted its holdings in Edwards Lifesciences by 23.4% in the 4th quarter. Integrated Wealth Concepts LLC now owns 9,790 shares of the medical research company's stock worth $725,000 after buying an additional 1,856 shares during the period. AQR Capital Management LLC boosted its holdings in Edwards Lifesciences by 43.5% in the 4th quarter. AQR Capital Management LLC now owns 208,889 shares of the medical research company's stock worth $15,464,000 after buying an additional 63,313 shares during the period. Finally, Keel Point LLC boosted its holdings in Edwards Lifesciences by 25.4% in the 4th quarter. Keel Point LLC now owns 4,814 shares of the medical research company's stock valued at $356,000 after purchasing an additional 976 shares during the period. 79.46% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several brokerages have commented on EW. BTIG Research raised shares of Edwards Lifesciences from a "neutral" rating to a "buy" rating and set a $100.00 price target for the company in a report on Tuesday, July 29th. Deutsche Bank Aktiengesellschaft raised their price target on shares of Edwards Lifesciences from $85.00 to $94.00 and gave the company a "buy" rating in a report on Friday, July 25th. Robert W. Baird raised their price target on shares of Edwards Lifesciences from $78.00 to $79.00 and gave the company a "neutral" rating in a report on Friday, July 25th. Royal Bank Of Canada raised their price target on shares of Edwards Lifesciences from $85.00 to $89.00 and gave the company an "outperform" rating in a report on Friday, July 25th. Finally, Canaccord Genuity Group raised their price target on shares of Edwards Lifesciences from $75.00 to $81.00 and gave the company a "hold" rating in a report on Friday, July 25th. Three analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating, ten have issued a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $85.90.

Insider Buying and Selling at Edwards Lifesciences

In related news, insider Larry L. Wood sold 8,950 shares of Edwards Lifesciences stock in a transaction on Monday, August 18th. The shares were sold at an average price of $78.06, for a total value of $698,637.00. Following the transaction, the insider owned 206,900 shares in the company, valued at $16,150,614. This trade represents a 4.15% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Daniel J. Lippis sold 4,114 shares of Edwards Lifesciences stock in a transaction on Monday, July 28th. The stock was sold at an average price of $79.46, for a total transaction of $326,898.44. Following the completion of the transaction, the vice president owned 22,002 shares in the company, valued at approximately $1,748,278.92. The trade was a 15.75% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 22,014 shares of company stock worth $1,698,844. Corporate insiders own 1.29% of the company's stock.

Edwards Lifesciences Price Performance

Shares of Edwards Lifesciences stock traded down $0.24 on Thursday, hitting $80.98. 2,501,007 shares of the company traded hands, compared to its average volume of 3,587,524. The firm's 50-day simple moving average is $78.71 and its 200 day simple moving average is $75.17. The company has a current ratio of 4.68, a quick ratio of 3.87 and a debt-to-equity ratio of 0.06. The company has a market cap of $47.55 billion, a P/E ratio of 11.65, a P/E/G ratio of 3.92 and a beta of 1.07. Edwards Lifesciences Corporation has a 12-month low of $64.00 and a 12-month high of $83.00.

Edwards Lifesciences (NYSE:EW - Get Free Report) last posted its quarterly earnings data on Thursday, July 24th. The medical research company reported $0.67 earnings per share for the quarter, beating the consensus estimate of $0.62 by $0.05. The firm had revenue of $1.53 billion for the quarter, compared to analysts' expectations of $1.49 billion. Edwards Lifesciences had a net margin of 72.96% and a return on equity of 15.01%. The business's quarterly revenue was up 11.9% on a year-over-year basis. During the same quarter last year, the company posted $0.70 EPS. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. Analysts expect that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current fiscal year.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.